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Preliminary and Incomplete 
 
Abstract 
We study individual demand for COVID-19 antibody tests in an incentivized study on a 
representative sample of the US population. Almost 2,000 participants trade off obtaining an at-
home test kit against money. At prices close to zero, 80 percent of individuals want the test. 
However, this broad support of testing falls sharply with price. Demand decreases by 19 
percentage points per $10 price increase. Demand for testing increases with factors related to its 
potential value, such as age, increased length and strength of protective immunity from 
antibodies, and greater uncertainty about having had the virus. Willingness to pay for antibody 
tests also depends on income, ethnicity and political views. Black respondents show significantly 
lower demand than white and Hispanic respondents, and Trump-supporters demonstrate 
significantly lower demand for testing. The results suggest that charging even moderate prices 
for antibody tests could widen health inequalities. 
 
JEL: D81, D91, I12, I18 









The COVID-19 pandemic has led to one of the largest death tolls in history and an 
unprecedented shutdown of economic activity worldwide. Having reduced the spread of the 
virus, some governments are starting to carefully open up again. As a major part of the return to 
“new normal”, testing is discussed in many countries, e.g., Germany (Dorn et al., 2020) or the 
US (Altmann et al., 2020). However, forcing such tests or requiring “immunity passports” seem 
highly controversial and problematic (Miller, 2020; Studdert and Hall, 2020). In a country of 
over 300 million inhabitants such as the US, knowledge about antibody status may ultimately 
depend on individuals’ willingness to test themselves privately.  
This paper measures individual willingness to pay for private COVID-19 antibody tests.  We 
conducted an incentivized study on a representative sample of almost 2,000 U.S. participants. 
When the study was launched, no at-home testing kit had been approved by the U.S. Food and 
Drug Administration (FDA) yet (U.S. FDA, 2020). We confronted participants with different 
scenarios. In each of them, we elicited willingness to pay for antibody testing. Four in five 
individuals would like to get tested, if it was basically for free. Yet, this changes drastically with 
price. For example, demand drops by half when the price of the test is $20 or more. Thus, the 
data demonstrate that price plays an important role.  
Demand for the test is influenced by test value. For example, older people and those who 
have experienced more deaths due to COVID-19 demand the test more frequently. Beliefs about 
antibody status also matter for demand.  It has been argued that people may overestimate chances 
of having had Covid-19 (Mandavilli, 2020). Our data reveals that indeed, compared to CDC 
estimates, most people tend to overestimate chances of having been infected. Yet most people 
feel uncertain. Test demand increases with this uncertainty. 
Several personal factors affect the demand for testing as well, such as income, age, ethnicity, 
and political views. We document that people of black ethnicity demand the test significantly 
less often. They are willing to pay approximately $5 less than whites for testing, even though 
they may be at higher risk of infection (Hlavinka, 2020). The data also show that Trump-
supporters demonstrate lower test demand, while those who approve of Dr. Fauci’s performance 
display significantly higher test demand. 
 Many studies on the prevalence of COVID-19 antibodies in populations so far rely on 
volunteers. Participation may often come with an extra effort for participants. Our data indicate 
that such an approach unlikely leads to a representative sample of the population as preferences 
for testing vary with many socio-economic characteristics. Even when controlling for some 
characteristics, such as age, gender and ethnicity, other factors such as political orientation will 
unlikely be controlled for. For example, Trump supporters may not only display a lower interest 
in testing, but also protect themselves less from Covid-19. If they take the disease less seriously 
but also test less, voluntary testing will systematically underestimate the prevalence of infection 
rates in the US population. 
Existing research has demonstrated that in some cases people avoid medical testing. For 
example, people at risk of the severe genetic Huntington’s Disease often opt against testing (see 
Caplin and Leahy 2001, Oster et al. 2013, Schweizer and Szech 2018). The same is true for 
people at risk of HIV, or Alzheimer’s (see Hertwig and Engel 2016 and Golman et al., 2017, for 
overviews on such deliberate ignorance). In this light, it may be good news that four out of five 
US citizens want an antibody test for COVID-19 when it comes for free. Thunström et al. 
(2020a, b) find similar willingness to get tested for the disease or vaccine take-up in hypothetical 
(and costless) decisions. Yet, our results demonstrate that this demand falls sharply with price. 
This result is important for policymakers that are “opening up” their economies and societies. 
Furthermore, demand for the test is not only driven by its value, but also by other factors such as 
income, race and political orientation. Pricing decisions could therefore have large impacts on 
health inequality.  
 
Experimental Design 
Our study is based on 1,984 participants, selected to represent the US population, who took part 
in our anonymous study. Each individual decided, in eight different testing scenarios, whether 
they preferred an antibody at-home testing kit or a voucher. The value of the voucher varied 
from $0.50 to $30 in each scenario, and came in the form of an Amazon gift card. Across 
scenarios, the protective immunity of antibodies varied. A positive test result could lead to a 
likelihood of protection from COVID-19 with 50%, 70%, 90%, or 99% chance. The expected 
length of protection also varied. It was either 3, 6, or 12 months. Eight out of the 12 possible 
testing scenarios were randomly chosen and presented to the individual in random order.  
Individuals knew that about 1 in 25 of them would be chosen randomly and one of their 
decisions would be implemented. We explained that their decisions would be implemented using 
the scenario that most closely fits the tests that become available in upcoming weeks. At the time 
of the study, it was uncertain which scenario would fit best to the test that would eventually 
become available on the market, and the protective immunity a positive test result may provide. 
Therefore, all scenarios were potentially relevant based on existing research (Altmann et al., 
2020; Sheridan, 2020). We calculate each individual’s willingness to pay for the test in each 
scenario based on the first voucher value for which the individual chooses the voucher over the 
test. This provides a maximum willingness to pay. More than 94% of individuals make 
consistent decisions and the analyses focus on them. After making their testing decisions, 
individuals responded to several questions about their beliefs and experiences with COVID-19, 
and individual characteristics. They were also presented with the choice between 2 antibody 
tests, instead of 1, and vouchers ranging between $0.50 and $75. It took about 12 minutes to 
participate in our study. Data elicitation took place from May 6 to May, 18 2020. 
 
Results 
Most people express an interest in testing for antibodies. About 80 percent of individuals 
demand a test when it costs less than $2. This result is robust to the different strength and length 
of protective immunity a positive test result may provide. As price increases demand drops, 
down to less than 20% when the price is $30 and the chance of protective immunity is rather 
low, 50% (see Figure 1). On average, a $10-dollar increase in the cost of the antibody test 
reduces demand by 19 percentage points (see Table 1, p<0.001).  
Increases in the length of the protective immunity offered by the test increase demand. As 
shown in Table 1, an increase in the length of immunity of 1 month, increases test demand by 0.8 
percentage points. In other words, people pay $0.95 more for a test, if a positive results result 
indicates protection from COVID-19 for 12 months than for 6 months. The increase in 
willingness to pay is not linear: it is stronger when immunity increases from 6 to 3 months 
($1.45), than when immunity increases from 6 to 12 months. This suggests that, given the current 
ambiguity on what the next months may bring, individuals mostly focus on the near future. 
Protection levels affect demand. An increase of 1 percentage point in the chance of 
protection increases demand by 0.3 percentage points. For example, people pay $0.90 more for a 
test, if a positive test result leads to a protection level of 99 percent than of 90 percent. For 
comparison, according to the CDC, the vaccine against measles has led to more than a 99 percent 
reduction of cases (Center for Disease Control and Prevention, 2019). In contrast, the flu vaccine 
needs to be adapted to each new flu season and often displays an effectiveness of about 50 
percent (Center for Disease Control and Prevention, 2020). Our results demonstrate that for 
COVID-19, people care a lot about protection levels.  
Using our elicitation method, we can further compare how individuals trade off increases in 
length and strength of protection. An increase in the chance of protection of 27 percentage points 
is equivalent to an increase in the length of protection of 10 months. Increases in strength and 
length of protective immunity also decrease the effect of price on demand (see columns (2)-(4) 
of Table 1). For example, even at a price of $30, 50% of individuals demand the test when the 
length of immunity is 12 months and the chance of protection is very high, i.e., 99%.  
 
[INSERT FIGURE 1 and TABLE 1 HERE] 
 
We also evaluate demand when individuals are offered two tests, instead of one. If the price 
of two tests is low, as with one test, most individuals choose the tests. As the price increases to 
$50 or $75, demand drops to 44% and 36%, respectively. This reveals that a minority of people 
would be willing to pay prices above $75 for testing (see detailed results in the SOM). About 33 
percent of individuals say they would use both tests on themselves, while 63 percent say they 
would pass one on to another person. 
Demand for the tests varies strongly by demographic. Figure 2 shows the maximum 
willingness to pay for an antibody test, averaged across scenarios. As shown in Figure 2 and 
columns (3)-(4) of Table 1, there is a significant increase in demand in older individuals, 
consistent with older individuals being at higher risk from death and other complications from 
COVID-19. Across ethnicities, demand is significantly lower for non-Hispanic blacks, compared 
to whites, and also to Hispanic individuals. On average, non-Hispanic blacks demand the test 11 
to 13 percentage points less than whites and are willing to pay $4.10 less than whites ($15.28 
compared to $19.38). As income increases, individuals are willing to pay more for the test, as 
one would expect as the price becomes a less important part of the household’s budget. 
Individuals’ work situation does not significantly affect demand. Relative to those who work 
from home (33% of the sample), those who are essential workers or lost their job due to COVID-
19 do not exhibit significantly different demand. Only those who are not employed, such as 
students or retired individuals, exhibit a weakly lower demand.  
 
[INSERT FIGURE 2 HERE] 
 
A central concern is that individuals overestimate their infection status, misattributing colds, 
allergies or regular flu to COVID-19. The New York Times stated in May that almost everybody 
in New York believed they had COVID-19 already (Mandavilli, 2020). In our representative 
sample of the US, we find that on average, people believe they had been infected already with a 
likelihood of 25 percent. This is very likely an over-estimate (see SOM for a US-state specific 
comparison to CDC estimates). Yet few people are certain or almost certain they have had 
COVID-19. Much more common are beliefs of 0 (19% of the sample), 20 (the median is 18), or 
50 percent (see Figure 3).   
Beliefs about infection of individuals can be compared with prevalence rates estimated by the 
Center for Disease Control and Prevention (CDC). We use the data as of May 10, 2020, 
published by the CDC for each state (see SOM for detailed results by state). The CDC provides 
an estimated range of percentage of positive cases. This range can be 0-5%, 6-10%, 11-20%, 21-
30%, 31-40%. Comparing individual responses across states, we find that in most states (86%), 
the average believed status of infection is above the CDC estimated range. For example, while 
the estimated range of positive cases is 6-10% in California, the average belief of participants in 
California regarding the likelihood that they have had COVID-19 is 25%. In 10% of the states, 
beliefs coincide with the CDC range, while in 4% of the states, individuals report a belief below 
that of the CDC estimated range. These results suggest that, while a majority of individuals 
believe that the chance they have had the virus is low, it may still be above official estimates.  
 
[INSERT FIGURE 3 HERE] 
 
Consistent with standard information economics, we find that willingness to pay for testing is 
significantly related to individuals’ self-reported beliefs about their infection status. Those who 
are certain to have had or not have had the virus, report the lowest willingness to take the test. 
The more uncertain individuals are about their infection status, the more they are willing to pay 
for testing as shown in Figure 3. Thus, patterns are consistent with individuals perceiving the test 
as providing instrumental information about infection status. We also elicited individuals’ beliefs 
that others in close proximity had been infected. This belief is highly correlated with own belief 
(Spearman correlation coefficient = 0.72, p-value<0.001) and does not have an independent 
effect on demand for the test.   
Individuals’ willingness to pay for the test is also related to their personal knowledge of 
people infected with the virus. The number of deaths in the individuals’ social circle is related to 
their demand for the test (column (4) of Table 1). While a relationship can also be found when 
considering COVID-19 cases instead of deaths, the relationship is generally weaker, suggesting 
that the largest driver of willingness to get tested is deaths, the worst outcome, rather than 
infections. Not surprisingly, those who have already been tested for COVID-19, approximately 
4% of the sample, display a lower demand for the test. At the same time, those individuals who 
report being worried or very worried about COVID-19 report a higher demand.  
Decisions about taking an antibody test may also depend on the understanding of probability 
values and updating information in a statistically correct way. A concern has been that antibody 
tests that exhibit low sensitivity, i.e., often showing a positive result for antibodies while the 
individual does not have any, can mislead people if they cannot account for the error rate of tests 
(Mandavilli, 2020; Hagmann et al., 2020). We therefore included four questions on statistical 
knowledge. Two questions were on probability estimates (regarding the chances of particular 
outcomes of a die roll). Overall, 42% of participants provided a correct answer to both questions, 
40% provided a correct answer to 1 question, and 18% did not answer either question correctly. 
We also added two incentivized questions to measure failures in Bayesian updating (Tversky and 
Kahnemann, 1974). These questions presented individuals with antibody tests that had an 
accuracy of either 90% or 95% (i.e., correctly detected antibodies with 90 or 95 chance), and a 
prevalence of COVID-19 infections of 5% or 20%. Each person saw two randomly drawn 
scenarios and was incentivized to correctly guess how likely a positive test result indicated the 
presence of antibodies. A common mistake in such questions is to ignore the “base rate” and 
report an accuracy equivalent to 90 or 95%. In the sample, 35% of participants exhibit Bayes rate 
neglect (Tversky and Kahnemann, 1974), while 42% of participants provide an answer that is 
within 10 percentage points of the correct answer.  We aggregate answers to the four questions 
on statistical knowledge into an index, adding all correct responses and standardizing it. 
Statistics knowledge is related to a stronger demand of the test. A one standard deviation 
increase in statistics knowledge is related to an increase in demand of 1.5 percentage points. This 
indicates that, despite the fact that some individuals understand the potential limitations of 
antibody tests very well, they value them (see column (4) of Table 1).  
In addition to personal characteristics and beliefs, an individual’s perception of how public 
authorities deal with the pandemic may affect test demand (Briscese et al., 2020; Fetzer et al., 
2020). Role models may have significant influence. Therefore, individuals rate the performance 
of Dr. Fauci and of President Trump during the Coronavirus crisis, from 0 (extremely bad) to 10 
(extremely good). Individuals who report a high degree of approval of Dr. Fauci exhibit a much 
higher willingness to pay for antibody tests. By contrast, those who rate the performance of 
President Trump as high exhibit a significantly lower willingness to pay for testing (see Figure 
4). This is consistent with ongoing research comparing individual perceptions over time (Fetzer 
et al., 2020), and also shows that within the US, perceptions of competence among public 
authorities could significantly influence individual behaviors during the pandemic. Of course, 
here, we cannot exclude reverse causality in the sense that people who do not like testing 
approve more of President Trump. 
 
[INSERT FIGURE 4 HERE] 
 
The value of the test also ultimately relies on individuals’ planned use of the information that 
they have (or do not have) antibodies. If individuals took the test and it detected antibodies, they 
indicated that they would engage in indoors and outdoors social activities, visit restaurants and 
malls, and return to work over 20% of the time. The largest fraction (over 40%) however 
indicated that they would not engage in any of these “risky” behaviors. This reveals that, for a 
substantial fraction of people, knowledge that they had antibodies would not be sufficient to lead 
to riskier, social behaviors. This suggests significant caution among individuals and perhaps 
assuages the concern that positive antibody test results could be interpreted as “freedom” from 
social distancing measures by most people.   
 
Conclusion  
Our results demonstrate that most people want an antibody test. Four in five US citizens demand 
a test if prices are close to zero. Yet this demand drops sharply as prices increase. At a cost of 
$20, demand roughly drops by half. People of black ethnicity are significantly less willing to pay 
for testing than other ethnicities. Yet research suggests that they may be at higher risk from 
Covid-19, not only for socio-economic, but also for genetic reasons (Cao et al., 2020). An 
analysis of past pandemics going back almost 1,000 years demonstrates that pandemics typically 
increase inequality (Wade, 2020). Policy makers should be aware that also in this pandemic 
inequality may rise.  If testing comes at a private cost, this could happen even more so, damaging 
groups of society that were already vulnerable before. Other hard-hit countries are currently 
aiming to provide free antibody testing (Nikolskaya and Voronova, 2020). From our data, this 
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Figure 1. This figure displays the fraction of respondents choosing the COVID-19 antibody tests, for each price. Demand
is shown for the cases in which protective immunity lasts 3 months (left), 6 months (center), and 12 months (right). In each
case, the strength of protective immunity varies between a 99%, 90%, 70% or 50% chance that antibodies offer protection
against COVID-19.
1
Figure 2. This figure displays the average willingness to pay for COVID-19 antibody tests, by gender, age, ethnicity and
household income. The shares of each demographic characteristic are representative of the US population. The horizontal
bars around each average represent ± 1 SE.
2
Figure 3. This figure displays the distribution of beliefs about COVID-19 Infection status, as of May 6-18 of 2020 (left
panel), and the relationship between this belief and individuals’ willingness to pay for COVID-19 antibody tests (right panel).
The black line is a polynomial fitted regression for the individual’s average willingness to pay, across all scenarios, as a
function of the individual’s belief about COVID-19 status with 95% confidence interval (shaded grey area).
3
Figure 4. This figure displays the results of polynomial fitted regressions for the individual’s average willingness to pay for
antibody tests, across all scenarios, as a function of the individual’s approval of President Trump’s (in blue) and Dr. Fauci’s



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.1 Descriptive Statistics of the Sample





Race: non-hispanic white 0.61
Race: non-hispanic black 0.13
Race: hispanic 0.18
Race: asian or other 0.08
Household income>75k in 2019 0.42
High school or less 0.28
College-level education or higher 0.67
Lives in city 0.31
Lives in suburban area 0.51





Working from home 0.29
Lost job due to COVID-19 0.12
Not employed (e.g., student, retired) 0.33
Other work situation 0.08
Observations 1984
6




Tested for COVID19 0.04
Chance I have had COVID19 already (0-100) 25.44
Chance close others have had COVID19 already (0-100) 25.55
COVID19 Dangerous due to underlying conditions 0.24
Worried about becoming infected with COVID19 0.36
Nr. of friends infected with COVID19 0.79
Nr. of friends died from COVID19 0.18
Predicted Deaths from COVID19 within 1 month 118802.73
Approval score for President Trump during COVID19 crisis 3.96
Approval score for Dr. Fauci during COVID19 crisis 6.80
Observations 1984
7
A.2 Demand and Willingness to Pay
Table A.3: Antibody Test Demand, by Price, Length and Strength of Immunity
(1) (2) (3) (4) (5) (6) (7) (8) (9)
All P=0.50 P=2 P=5 P=10 P=15 P=20 P=25 P=30
mean mean mean mean mean mean mean mean mean
3 month - 50% 0.48 0.81 0.77 0.68 0.52 0.41 0.28 0.21 0.17
6 month - 50% 0.52 0.81 0.79 0.71 0.60 0.47 0.33 0.26 0.21
12 month - 50% 0.54 0.81 0.79 0.71 0.60 0.50 0.37 0.28 0.23
3 month - 70% 0.56 0.86 0.82 0.76 0.62 0.52 0.39 0.30 0.24
6 month - 70% 0.60 0.86 0.84 0.78 0.67 0.58 0.44 0.35 0.27
12 month - 70% 0.63 0.87 0.85 0.80 0.70 0.61 0.49 0.41 0.34
3 month - 90% 0.61 0.85 0.83 0.78 0.68 0.57 0.47 0.36 0.31
6 month - 90% 0.65 0.86 0.85 0.80 0.72 0.64 0.52 0.43 0.37
12 month - 90% 0.69 0.86 0.85 0.82 0.75 0.69 0.60 0.52 0.45
3 month - 99% 0.64 0.86 0.84 0.79 0.69 0.60 0.51 0.43 0.38
6 month - 99% 0.69 0.87 0.85 0.81 0.75 0.68 0.59 0.50 0.44
12 month - 99% 0.71 0.87 0.85 0.82 0.76 0.71 0.62 0.56 0.50
Observations 15872 1984 1984 1984 1984 1984 1984 1984 1984
Table A.4: Antibody Test Willingness to Pay, by Length and Strength of Immunity
(1) (2) (3) (4)
50% immunity 70% immunity 90% immunity 99% immunity
mean mean mean mean
3-month immunity 14.39 17.14 18.62 19.61
6-month immunity 15.82 18.41 20.03 21.24
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Figure A.1: This figure displays the fraction of non-Hispanic blacks choosing the COVID-19 antibody tests, for each price.
Demand is shown for the cases in which protective immunity lasts 3 months (left), 6 months (center), and 12 months (right).
In each case, the strength of protective immunity varies between a 99%, 90%, 70% or 50% chance that antibodies offer
protection against COVID-19.
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Figure A.2: This figure displays the average willingness to pay for antibody tests, by chance of immunity (left panel) and
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Figure A.3: This figure displays the fraction of subjects who demand the 2 antibody tests, over each available monetary
payment, separated by those who indicated they would share the 2 tests with someone else or use them for themselves.
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A.3 Willingness to Pay by State and CDC Statistics
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Table A.5: Willingness to Pay and Beliefs by US State
CDC Data (May 12, 2020) Study Data
Total Total Percent Belief I Willingness
Cases Death Category had COVID19 to pay (in $) N
Alabama 10413 424 2 20.65 18.31 26
Alaska 381 10 1 52.50 25.94 2
Arizona 11380 542 2 23.24 21.28 54
Arkansas 4043 94 5 26.08 17.93 13
California 67939 2770 5 24.93 17.92 245
Colorado 19735 986 2 37.77 19.19 43
Connecticut 33765 3008 3 34.17 22.96 18
Delaware 6741 237 3 25.17 21.08 6
District of Columbia 6389 328 3 17.33 22.78 3
Florida 40982 1735 5 21.06 18.53 177
Georgia 33995 1442 2 23.79 15.84 77
Hawaii 582 17 1 20.33 11.17 3
Idaho 2260 70 1 28.25 10.97 4
Illinois 79007 3459 3 30.80 18.53 96
Indiana 24627 1540 3 24.62 21.81 24
Iowa 12373 271 3 30.10 18.12 10
Kansas 7116 158 2 31.75 19.60 12
Kentucky 6677 311 5 18.52 15.37 21
Louisiana 31881 2308 2 23.44 18.33 25
Maine 1462 65 5 14.62 18.11 8
Maryland 34061 1756 3 22.38 21.29 37
Massachusetts 78462 5108 2 24.00 19.51 39
Michigan 47552 4584 2 26.33 18.09 45
Minnesota 11799 591 5 26.09 19.36 32
Mississippi 9908 457 5 16.70 14.08 10
Missouri 9918 488 5 23.32 17.40 37
Montana 459 16 1 50.00 7.50 1
Nebraska 8572 100 3 22.50 16.87 14
Nevada 6163 317 2 27.62 22.16 26
New Hampshire 3160 133 5 20.80 21.14 10
New Jersey 139945 9310 4 22.14 20.99 65
New Mexico 5069 208 5 22.75 20.67 16
New York 336017 27184 3 31.60 19.33 157
North Carolina 15045 550 2 24.59 15.48 71
North Dakota 1518 36 1 33.00 20.00 1
Ohio 24777 1357 5 27.33 19.08 72
Oklahoma 4439 269 1 29.73 14.28 22
Oregon 3286 130 1 28.61 20.44 18
Pennsylvania 57154 3731 2 26.16 19.83 99
Rhode Island 11450 430 2 25.17 15.88 6
South Carolina 7792 346 2 33.62 15.75 21
South Dakota 3614 34 2 15.00 25.62 3
Tennessee 15622 251 5 22.30 19.20 33
Texas 39869 1100 5 21.41 18.41 149
Utah 6395 72 1 29.67 15.33 12
Vermont 926 53 1 16.00 13.33 3
Virginia 25800 891 2 23.20 21.04 45
Washington 17122 945 5 28.10 19.26 31
West Virginia 1369 57 1 15.00 25.21 6
Wisconsin 10418 409 5 24.20 19.01 35
Wyoming 669 7 1 66.67 11.19 3
Notes: Percent category is the percent range of positive cases provided by the CDC under
https://www.cdc.gov/covid-data-tracker/index.html. The value of 1 is 0-5%, 2 is 11-20%, 3 is 21-30%, 4 is
31-40% and 5 is 6-10% of the population in the state is estimated to have COVID19.
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A.4 Self-reported Planned Behavior after Testing
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Figure A.4: This figure displays the frequency with which each option was chosen when subjects were asked “Suppose you took a Coronavirus
antibody test, and the result came back positive, indicating antibodies. Which of the following behaviors do you think you would engage in immediately
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